Lennox-Gastaut Syndrome (LGS) Therapeutics Pipeline to Witness Significant Growth Due to Positive Clinical Trial Results in the Coming Years
LGS is a rare and severe form of epilepsy that mostly affects individuals during infancy or early childhood. This syndrome has the tendency to develop between the age of one to eight years in children, and can be characterized by polymorphic seizures and neuropsychological decline. The cause of this syndrome can be symptomatic, which is secondary to an underlying brain disorder or it can be cryptogenic, which means the exact cause of the disease is unknown.
View full press release